Fig. 4From: Real-world effectiveness of omalizumab for severe allergic asthma treatment in ColombiaPrebonchodilator FEV1 assessment at starting omalizumab and follow-up. The percentage of patients with a prebronchodilator FEV1 < 80% consistently decreased and, on the contrary, the percentage of patients with prebronchodilator FEV1 ≥ 80% significantly increased after omalizumab initiationBack to article page